Literature DB >> 31185202

Postcardiotomy Venoarterial Extracorporeal Membrane Oxygenation in Patients Aged 70 Years or Older.

Fausto Biancari1, Diyar Saeed2, Antonio Fiore3, Magnus Dalén4, Vito G Ruggieri5, Kristján Jónsson6, Giuseppe Gatti7, Svante Zipfel8, Angelo M Dell'Aquila9, Sidney Chocron10, Karl Bounader11, Gilles Amr5, Nicla Settembre12, Kristiina Pälve13, Antonio Loforte14, Marco Gabrielli7, Ugolino Livi15, Andrea Lechiancole15, Marek Pol16, Ivan Netuka16, Cristiano Spadaccio17, Matteo Pettinari18, Dieter De Keyzer18, Daniel Reichart8, Sigurdur Ragnarsson19, Khalid Alkhamees20, Artur Lichtenberg2, Thomas Fux4, Zein El Dean21, Mariafrancesca Fiorentino14, Giovanni Mariscalco21, Anders Jeppsson6, Henryk Welp9, Andrea Perrotti10.   

Abstract

BACKGROUND: There is uncertainty whether venoarterial extracorporeal membrane oxygenation (VA-ECMO) should be used in older patients with cardiopulmonary failure after cardiac surgery.
METHODS: This was a retrospective multicenter study of 781 patients who required postcardiotomy VA-ECMO for cardiopulmonary failure after adult cardiac surgery from 2010 to 2018 at 19 cardiac surgery centers. A parallel systematic review with meta-analysis of the literature was performed.
RESULTS: The hospital mortality in the overall Postcardiotomy Venoarterial Extracorporeal Membrane Oxygenation (PC-ECMO) series was 64.4%. A total of 255 patients were 70 years old or older (32.7%), and their hospital mortality was significantly higher than in younger patients (76.1% vs 58.7%; adjusted odds ratio, 2.199; 95% confidence interval [CI], 1.536 to 3.149). Arterial lactate level greater than 6 mmol/L before starting VA-ECMO was the only predictor of hospital mortality among patients 70 years old or older in univariate analysis (82.6% vs 70.4%; P = .029). Meta-analysis of current and previous studies showed that early mortality after postcardiotomy VA-ECMO was significantly higher in patients aged 70 years or older compared with younger patients (odds ratio, 2.09; 95% CI, 1.59 to 2.75; 5 studies including 1547 patients; I2, 5.9%). The pooled early mortality rate among patients aged 70 years or older was 78.8% (95% CI, 74.1 to 83.5; 6 studies including 617 patients; I2, 41.8%). Two studies reported 1-year mortality (including hospital mortality) of 79.9% and 75.6%, respectively, in patients 70 years old or older.
CONCLUSIONS: Advanced age should not be considered a contraindication for postcardiotomy VA-ECMO. However, in view of the high risk of early mortality, meaningful scrutiny is needed before using VA-ECMO after cardiac surgery in older patients.
Copyright © 2019 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2019        PMID: 31185202     DOI: 10.1016/j.athoracsur.2019.04.063

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  3 in total

1.  30-Day perioperative mortality following venoarterial extracorporeal membrane oxygenation for postcardiotomy cardiogenic shock in patients with normal preoperative ejection fraction.

Authors:  Priya R Menon; Anna Flo Forner; Mateo Marin-Cuartas; Sven Lehmann; Diyar Saeed; André Ginther; Michael A Borger; Jörg Ender
Journal:  Interact Cardiovasc Thorac Surg       Date:  2021-05-10

2.  Venoarterial Extracorporeal Membrane Oxygenation for Postcardiotomy Shock-Analysis of the Extracorporeal Life Support Organization Registry.

Authors:  Mariusz Kowalewski; Kamil Zieliński; Daniel Brodie; Graeme MacLaren; Glenn Whitman; Giuseppe M Raffa; Udo Boeken; Kiran Shekar; Yih-Sharng Chen; Christian Bermudez; David D'Alessandro; Xiaotong Hou; Jonathan Haft; Jan Belohlavek; Inga Dziembowska; Piotr Suwalski; Peta Alexander; Ryan P Barbaro; Mario Gaudino; Michele Di Mauro; Jos Maessen; Roberto Lorusso
Journal:  Crit Care Med       Date:  2021-07-01       Impact factor: 9.296

3.  Commentary: Extracorporeal membrane oxygenation: Is it life-saving and cost effective for all patients?

Authors:  Harold L Lazar
Journal:  JTCVS Open       Date:  2020-03-03
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.